AcuityMD has secured $80 million in funding to expand its AI-powered platform, focusing on agentic AI capabilities that enable smarter decision making and automation across the medical technology lifecycle.
Glimpse:
Announced in April 2026, AcuityMD raised $80 million in a Series C round led by StepStone Group, with participation from Benchmark, Redpoint, ICONIQ, and Atreides. The funding will accelerate development of agentic AI tools, enhance its MedTech data platform, and expand capabilities across commercial, research, and product lifecycle functions.
AcuityMD has raised $80 million in Series C funding, marking a significant step in advancing AI-driven innovation within the medical technology industry. The round was led by StepStone Group, alongside major investors including Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management.
With this funding, the company plans to scale its agentic AI capabilities, particularly through its platform “AcuityAI,” which enables users to ask complex business questions and receive actionable insights instantly. These AI agents are designed to support commercial teams by providing recommendations on market trends, territory planning, and sales strategies.
AcuityMD’s platform aggregates fragmented healthcare data including claims, regulatory filings, and hospital data into a structured MedTech ontology, allowing organizations to better understand market dynamics and accelerate adoption of medical technologies.
Currently, the platform is used by over 400 MedTech companies, including 16 of the top 20 global players, and has helped identify more than $34 billion in commercial pipeline opportunities.
Beyond commercial use cases, the company plans to expand its AI capabilities across the entire product lifecycle, including research, development, and product launches. This positions AcuityMD as more than just a sales intelligence tool evolving into a comprehensive AI platform for the MedTech ecosystem.
The funding brings AcuityMD’s total capital raised to over $160 million, with a valuation approaching $955 million, reflecting strong investor confidence in AI-driven healthcare solutions.
Industry experts note that agentic AI—systems capable of autonomous decision making and task execution is emerging as a key trend in healthcare technology. By embedding such capabilities into MedTech workflows, companies like AcuityMD aim to improve efficiency, reduce manual effort, and enable faster adoption of innovative medical devices.
Overall, the funding highlights a broader shift toward AI-powered, data driven commercialization and innovation in healthcare, where intelligent systems are increasingly taking on complex operational roles.
“Agentic AI will redefine how MedTech teams operate and make decisions.”
By
HB Team
Related News
